.Space rocket high soon ,once I know the Pfizer is more effective than mck,I switch all my portfolios of mck to Pfizer.
Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
CNTB Connect Biopharma
1.150-0.070-5.74%
Close
02/03 16:00 ET
1.130-0.020-1.75%
Post Mkt Price 02/03 17:01 ET
High
1.210
Open
1.170
Turnover
37.73K
Low
1.135
Pre Close
1.220
Volume
32.05K
Post-Market
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
Sign in to post a comment
Like
Comment
Share
ColumnToday's pre-market stock movers: BBBY, CCL, SHOP, GIS and more
Gainers:
• $Allena Pharmaceuticals(ALNA.US$ stock is rocketing more than 93% after terminating an at-the-market sales agreement brought heavy trading.
• $Akebia Therapeutics(AKBA.US$ shares are surging over 54% alongside heavy trading this morning.
• $First Wave BioPharma(FWBI.US$ stock is soaring more than 28% with heaving early morning trading.
• $Connect Biopharma(CNTB.US$ shares are rising over 27% on heavy pre-market trading....
• $Allena Pharmaceuticals(ALNA.US$ stock is rocketing more than 93% after terminating an at-the-market sales agreement brought heavy trading.
• $Akebia Therapeutics(AKBA.US$ shares are surging over 54% alongside heavy trading this morning.
• $First Wave BioPharma(FWBI.US$ stock is soaring more than 28% with heaving early morning trading.
• $Connect Biopharma(CNTB.US$ shares are rising over 27% on heavy pre-market trading....
Like
Comment
Share
ColumnTop upgrades and downgrades on 6/2
Upgrades
• $Agree Realty Corp(ADC.US$: BofA Securities Upgrades Agree Realty (ADC) to Buy
• $Americold Realty Trust(COLD.US$: BofA Securities Upgrades to Neutral from Underperform - PT $30 (from $28)
• $Ecolab(ECL.US$: UBS Upgrades to Buy from Neutral - PT $205 (from $186)
• $Reinsurance Group of America(RGA.US$: Credit Suisse Upgrades to Neutral from Underperform - PT $122 (from $80)
• $SolarEdge Technologies(SEDG.US$: Oppenheimer Upgrades to Out...
• $Agree Realty Corp(ADC.US$: BofA Securities Upgrades Agree Realty (ADC) to Buy
• $Americold Realty Trust(COLD.US$: BofA Securities Upgrades to Neutral from Underperform - PT $30 (from $28)
• $Ecolab(ECL.US$: UBS Upgrades to Buy from Neutral - PT $205 (from $186)
• $Reinsurance Group of America(RGA.US$: Credit Suisse Upgrades to Neutral from Underperform - PT $122 (from $80)
• $SolarEdge Technologies(SEDG.US$: Oppenheimer Upgrades to Out...
Like
Comment
Share
$Connect Biopharma(CNTB.US$ still got chance to going back $3?
Like
Comment
Share
ColumnTop upgrades and downgrades on 5/5
Upgrades
• $AGNC Investment Corp(AGNC.US$ : Piper Sandler Upgrades to Overweight from Neutral - PT $13 (from $13.50)
• $Esperion Therapeutics(ESPR.US$ : JP Morgan Upgrades to Neutral From Underweight
• $Fortinet(FTNT.US$ : Mizuho Securities Upgrades to Buy from Neutral - PT $350 (from $340)
• $Horizon Technology Finance(HRZN.US$ : Compass Point Upgrades to Neutral From Sell
• $Momentive Global(MNTV.US$ : Craig-Hallum Upgrades to Buy from Hold - PT $...
• $AGNC Investment Corp(AGNC.US$ : Piper Sandler Upgrades to Overweight from Neutral - PT $13 (from $13.50)
• $Esperion Therapeutics(ESPR.US$ : JP Morgan Upgrades to Neutral From Underweight
• $Fortinet(FTNT.US$ : Mizuho Securities Upgrades to Buy from Neutral - PT $350 (from $340)
• $Horizon Technology Finance(HRZN.US$ : Compass Point Upgrades to Neutral From Sell
• $Momentive Global(MNTV.US$ : Craig-Hallum Upgrades to Buy from Hold - PT $...
Like
Comment
Share
ColumnToday's pre-market stock movers: AMD, SBUX, ABNB, MRNA and more
Gainers:
• $Livent(LTHM.US$ +22.58% (it posted better-than-expected quarterly earnings and raised its 2022 revenue forecast)
• $Super Micro Computer(SMCI.US$ +11.01% (earnings reports)
• $Oatly Group AB(OTLY.US$ +8.31% (earnings reports)
• $BlueLinx Holdings(BXC.US$ +9.7% (increases share repurchase authorization to $100 mln; enters into $60 mln accelerated repurchase agreement)
• $Starbucks(SBUX.US$ +7.18% (matched estimates wi...
• $Livent(LTHM.US$ +22.58% (it posted better-than-expected quarterly earnings and raised its 2022 revenue forecast)
• $Super Micro Computer(SMCI.US$ +11.01% (earnings reports)
• $Oatly Group AB(OTLY.US$ +8.31% (earnings reports)
• $BlueLinx Holdings(BXC.US$ +9.7% (increases share repurchase authorization to $100 mln; enters into $60 mln accelerated repurchase agreement)
• $Starbucks(SBUX.US$ +7.18% (matched estimates wi...
Like
Comment
Share
The Week Ahead In Biotech (Nov. 21-Nov. 27)
Biotech stocks showed a lack of direction in the week ending Nov. 19 before finishing modestly higher. Stocks did not have much meaningful catalysts to react to amid the winding down of the reporting season and ahead of the holiday week.
Among the major news of the week was $Pfizer(PFE.US$ filing an application for emergency use authorization for its oral COVID-19 pill Paxlovid. The company also bagged a $5.29 billion contract from the U.S. government to supply the investigational antiviral treatment and announced a voluntary license agreement with a U.N.-backed body to facilitate greater access to the global population.
$Biogen(BIIB.US$ was also in the news due to long-time company veteran and R&D head Alfred Sandrock, who oversaw the development of many breakthrough neurological treatments, announcing his retirement.
$Connect Biopharma(CNTB.US$ came under intense selling pressure after what seemed like positive topline data from the Phase 2 study of its investigational therapy CBP-201 in atopic dermatitis. Lack of efficacy details from each arm of the study irked investors, as they could not weigh in vis-à-vis existing treatments.
On the other hand, $Longeveron(LGVN.US$ shares nearly doubled during the week after its Lomecel-B for hypoplastic left heart syndrome drug received a rare pediatric disease designation from the Food and Drug Administration.
Among the major news of the week was $Pfizer(PFE.US$ filing an application for emergency use authorization for its oral COVID-19 pill Paxlovid. The company also bagged a $5.29 billion contract from the U.S. government to supply the investigational antiviral treatment and announced a voluntary license agreement with a U.N.-backed body to facilitate greater access to the global population.
$Biogen(BIIB.US$ was also in the news due to long-time company veteran and R&D head Alfred Sandrock, who oversaw the development of many breakthrough neurological treatments, announcing his retirement.
$Connect Biopharma(CNTB.US$ came under intense selling pressure after what seemed like positive topline data from the Phase 2 study of its investigational therapy CBP-201 in atopic dermatitis. Lack of efficacy details from each arm of the study irked investors, as they could not weigh in vis-à-vis existing treatments.
On the other hand, $Longeveron(LGVN.US$ shares nearly doubled during the week after its Lomecel-B for hypoplastic left heart syndrome drug received a rare pediatric disease designation from the Food and Drug Administration.
Like
Comment
Share
No comment yet
Company Overview
More
Connect Biopharma Holdings Ltd. engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. Its lead product candidate, CBP-201, is an antibody designed to target interleukin-4 receptor alpha, or IL-4Ra, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis and asthma. The company was founded by Zheng Wei and Wu Bin Pan on November 23, 2015 and is headquartered in Taicang, China.
CEO： Dr. Zheng Wei, PhD
Market： NASDAQ
Listing Date： 03/19/2021
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet